Merck & Co Inc

NYSE:MRK  
71.65
-0.32 (-0.44%)
5:28:11 PM EDT: $71.40 -0.25 (-0.35%)
Products

FDA Approves Updated Indication For Merck’S Keytruda (Pembrolizumab) For Treatment Of Certain Patients With Urothelial Carcinoma (Bladder Cancer)

Published: 08/31/2021 20:15 GMT
Merck & Co Inc (MRK) - FDA Approves Updated Indication for Merck’s Keytruda® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (bladder Cancer).
FDA Approves Updated Indication for Merck’s Keytruda® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (bladder Cancer).
Merck - Keytruda Approved for Treatment of Patients With Urothelial Carcinoma Who Are Not Eligible for Any Platinum-containing Chemotherapy.